REFERENCES
- Palmer D'Angelo Consulting Inc. Generic drug prices: A Canada US compari-son. Ottawa: PDCI Report Series; August 2002. www.pdci.on.ca/pdf/Generic% 20Pricing%20Study%20Final%20Report.pdf.
- Danzon PM, Furukawa NfF. Prices and availability of pharmaceuticals: Evidence from nine countries. Health Aff 2004; W3:521–36.
- Grootendorst P, DiMatteo L. The effect of pharmaceutical patent term length on research and development and drug expenditures: Evidence from Canada. Mimeo. To-ronto, Ontario: University of Toronto; 2004. individual.utoronto.ca/grootendorst/pdf/ DrugPatents.pdf.
- Organization for Economic Cooperation and Development (OECD). Research and development expenditure in industry 1987–2000: 2002 edition. Paris: OECD; 2002.
- Canadian Institute for Health Information. Drug expenditure in Canada 1985–2002. Ottawa: CIHI; 2003.
- Patented Medicine Prices Review Board. 2002 annual report. Ottawa: PMPRB; 2003. www.pmprb.com/CNfFiles/ar2002e21LEF- 6252003–6142. pdf.
- Grootendorst P. Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: History and assessment. Can J Clin Pharmacol. 2002; 9:79–99.
- Gross DJ. The consumer and reimportation. Managed Care. 2004; 13(3):43–4.